Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

The Journal of experimental medicine - 1 Jan 1992

Shalaby M R, Shepard H M, Presta L, Rodrigues M L, Beverley P C, Feldmann M, Carter P

Abstract excerpt

The HER2 protooncogene encodes a 185-kD transmembrane phosphoglycoproteins, human epidermal growth factor receptor 2 (p185HER2), whose amplified expression on the cell surface can lead to malignant transformation. Overexpression of HER2/p185HER2 is strongly correlated with progression of human ovarian and breast carcinomas. Recent studies have shown that human T cells can be targeted with bispecific antibody to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Base Sequence

Share to Cloning, Molecular

Share to Genetic Variation

Share to Models, Molecular

Share to Molecular Sequence Data

Share to Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 1346155
DOI: 10.1084/jem.175.1.217
PMCID: PMC2119072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.PMID 1346155Read ↗

Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin.Semantic proximity Read ↗

Bispecific antibodies for immune cell retargeting against cancerSemantic proximity Read ↗

An efficient route to human bispecific IgG.Semantic proximity Read ↗

Targeting cancer with bispecific antibodies.Semantic proximity Read ↗

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read ↗

Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats.Semantic proximity Read ↗

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagersSemantic proximity Read ↗

T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody FragmentSemantic proximity Read ↗

Human plasma cells engineered to secrete bispecifics drive effective <i>in vivo</i> leukemia killingSemantic proximity Read ↗

A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor ActivitySemantic proximity Read ↗

Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors.Semantic proximity Read ↗

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.